Project

A phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Amyloid Depleter ALXN2220 in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Scheduled ยท 2024 until 2029

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Scheduled
Start Date
2024
End Date
2029
Financing
Industry
Phase
III
Brief description/objective